1,660 results match your criteria Nonseminomatous Testicular Tumors


Incident testicular cancer in relation to using marijuana and smoking tobacco: A systematic review and meta-analysis of epidemiologic studies.

Urol Oncol 2020 May 11. Epub 2020 May 11.

Department of Preventive Medicine, Keck School of Medicine of USC, Los Angeles, CA; Department of Obstetrics and Gynecology, Keck School of Medicine of USC, Los Angeles, CA. Electronic address:

Background: Recent epidemiologic studies identified credible associations between marijuana smoking and risk of nonseminomatous testicular germ cell tumors (TGCTs), but did not distinguish exposure to cannabinoid compounds from exposure to other constituents of smoke.

Methods: We implemented a systematic review of scholarly literature followed by random effects meta-analysis to quantitatively synthesize published data relating incident TGCT to each of 2 exposure histories: ever using marijuana, and ever smoking tobacco.

Results: We identified four epidemiologic studies of marijuana use and 12 of tobacco smoking. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2020.03.013DOI Listing

Unusual Chemotherapeutic Resistant Testicular Embryonal Germ Cell Tumor with Widespread Metastasis in a Case of Klinefelter Syndrome: A Case Report.

Cureus 2020 Apr 11;12(4):e7637. Epub 2020 Apr 11.

Medical Oncology, Larkin Community Hospital, Miami, USA.

Cryptorchidism is an undeniable risk factor for testicular germ cell tumors (TGCTs) and is also commonly associated with Klinefelter syndrome (KS) patients. Embryonal cell carcinoma usually shows strong expression of CD30 and OCT3/4, with patchy staining of PLAP1. Most patients with nonseminomatous GCTs (NSGCTs) can achieve total remission with proactive chemotherapy, and most can be cured. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.7637DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213769PMC

Incidence and long-term effects of treatment of malignant germ cell neoplasms in Ukraine.

Exp Oncol 2020 03;42(1):66-74

National Cancer Registry of Ukraine, National Cancer Institute, Kyiv 03022, Ukraine.

Aim: To describe incidence of malignant germ cell neoplasms (GCNs) in Ukraine and assess the medical care to patients with GCNs and its efficacy.

Materials And Methods: Records on 6495 males and 1038 females with malignant GCNs diagnosed in 2000-2013 extracted from the database of National Cancer Registry of Ukraine have been analyzed using methods of descriptive epidemiology and survival evaluation.

Results: In Ukraine, GCNs covered 79. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.32471/exp-oncology.2312-8852.vol-42-no-1.14235DOI Listing

Meningothelial Meningioma Component in a Prepubertal Testicular Teratoma.

Case Rep Pathol 2020 20;2020:6495321. Epub 2020 Jan 20.

Department of Paediatric Surgery, AIIMS, Patna, India.

Teratomas are nonseminomatous germ cell tumors composed of elements derived from more than one germinal layers (endoderm, mesoderm, and ectoderm). Malignant transformation of teratoma in the testis is well known; however, benign somatic neoplasm arising in a testicular teratoma is a rare occurrence. We report a case of meningothelial variant of meningioma arising in a pure and mature teratoma of the testis in a 5-year-old boy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2020/6495321DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6995479PMC
January 2020

Current management and management controversies in early- and intermediate-stage of nonseminoma germ cell tumors.

Transl Androl Urol 2020 Jan;9(Suppl 1):S45-S55

Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.

Early stage nonseminomatous germ cell tumor (NSGCT) remains a treatable disease, with stage I cancer specific survival exceeding 95%. Using a risk-adapted approach; active surveillance (AS), adjuvant chemotherapy, and retroperitoneal lymph node dissection (RPLND) all options for treatment; with surveillance being increasingly used. With persistently elevated markers (stage IS), chemotherapy remains the hallmark of treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/tau.2019.05.14DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6995850PMC
January 2020

Immunohistochemical characterization of the anti-Müllerian hormone receptor type 2 (AMHR-2) in human testes.

Endocrine 2020 Apr 6;68(1):215-221. Epub 2020 Feb 6.

Centre of Reproductive Medicine and Andrology, University Hospital of Münster, Albert-Schweitzer Campus 1, 48149, Münster, Germany.

Purpose: In males, AMH is secreted by immature Sertoli cells; following exposure to endogenous androgens, Sertoli cells undergo a process of maturation which ultimately inhibits AMH expression to undetectable levels in the serum. However, expression of AMH receptor (AMHR-2) has never been studied in human testes, and high intratubular concentrations of AMH have been reported in recent literature. We therefore assessed expression of AMHR-2 in several testicular tissue samples by immunohistochemistry (IHC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12020-020-02210-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7160062PMC

Disorder of sex development with germ cell tumors: Which is uncovered first?

Pediatr Blood Cancer 2020 Apr 4;67(4):e28169. Epub 2020 Feb 4.

Institut de Pathologie Multisite, Groupement hospitalier Est, Hospices Civils de Lyon, UCBL Lyon 1 University, Lyon, France.

Background: Disorders of sex development (DSD) are rare conditions. Although they are known to predispose to germ cell tumors (GCT), there is a paucity of information regarding the circumstances of DSD discovery.

Design/methods: All patients with DSD registered in two French pediatric GCT protocols (TGM95 and 13) were analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pbc.28169DOI Listing
April 2020
2.562 Impact Factor

Role of primary retroperitoneal lymph node dissection in stage I and low-volume metastatic germ cell tumors.

Curr Opin Urol 2020 Mar;30(2):251-257

Department of Urology, USC/Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, USA.

Purpose Of Review: Early-stage testicular cancers are highly curable. Following orchidectomy, management options for stage I disease include active surveillance, nerve-sparing retroperitoneal lymph node dissection (nsRPLND) and primary chemotherapy as recommended by the current guidelines. Primary RPLND has for decades played an integral part of treatment in patients with early-stage testicular germ cell tumors (TGCT), particularly in nonseminomatous germ cell tumors (NSGCT) with focus on reducing the long-term morbidity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOU.0000000000000736DOI Listing

Prediction models for the viability of pulmonary metastatic lesions after chemotherapy in nonseminomatous germ cell tumors.

Int J Urol 2020 Mar 8;27(3):206-212. Epub 2020 Jan 8.

Division of Thoracic Surgery, Department of Surgery, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Objectives: To analyze predictors associated with viable cells in pulmonary residual lesions after chemotherapy for metastatic testicular nonseminomatous germ cell tumors and to develop models to prioritize pulmonary resection.

Methods: Between 2008 and 2017, 40 patients underwent pulmonary metastasectomy after chemotherapy for nonseminomatous germ cell tumors. We evaluated these patients, and 326 pulmonary residual lesions were confirmed using computed tomography and pathological evaluations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/iju.14162DOI Listing

[Management of residual masses of testis germ cell tumors].

Bull Cancer 2020 Feb 24;107(2):215-223. Epub 2019 Dec 24.

Hôpital Nord, service d'urologie, avenue Albert-Raimond, 42270 Saint-Priest-en-Jarez, France.

A residual mass (RM) is an abnormal image with a transverse axis of more than 1cm trans that remains visible on the CT scan performed after chemotherapy for metastatic germ cell tumors. Their management depends on the histology of the initial tumor. In the case of a non-seminomatous germ cell tumor, all residual lesions must be resected if the tumor markers are negative. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2019.10.010DOI Listing
February 2020

The relationship of neutrophil to lymphocyte ratio with testicular cancer.

Int Braz J Urol 2020 Jan-Feb;46(1):101-107

Department of Urology, Faculty of Medicine, Bezmialem Vakıf University, Istanbul, Turkey.

Purpose: To assess the relationship between testicular germ cell tumors (TGCT) and neutrophil to lymphocyte ratio (NLR) and to determine whether this ratio can be used as a serum tumor marker.

Material And Methods: Sixty-one patients with testicular germ cell tumors were included into the study. Patients were grouped as localized and non-localized. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1590/S1677-5538.IBJU.2019.0321DOI Listing
February 2020

OCT4 immunohistochemistry after staging laparoscopic retroperitoneal lymphadenectomy for testicular tumor.

Acta Clin Croat 2019 Jun;58(2):343-347

1Department of Urology, Zagreb University Hospital Centre and School of Medicine, University of Zagreb, Zagreb, Croatia; 2Department of Pathology and Cytology, Zagreb University Hospital Centre and School of Medicine, University of Zagreb, Zagreb, Croatia.

Twenty to thirty percent of patients with clinical stage I testicular tumor have metastases in the retroperitoneum. The aim of this study was to evaluate the role of OCT4 immunohistochemistry in histopathologic diagnosis of lymph node metastases in patients with nonseminomatous germ cell testicular tumors. All clinical stage I patients with staging laparoscopic retroperitoneal lymphadenectomy from 2001 until 2009 were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.20471/acc.2019.58.02.19DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6884368PMC

Retroperitoneal Lymph Node Dissection as Primary Treatment for Men With Testicular Seminoma: Utilization and Survival Analysis Using the National Cancer Data Base, 2004-2014.

Clin Genitourin Cancer 2020 Apr 6;18(2):e194-e201. Epub 2019 Nov 6.

Division of Urology, Rutgers Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ; Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ. Electronic address:

Background: The role of retroperitoneal lymph node dissection (RPLND) as first-line treatment for testicular seminoma is less well defined than for testicular nonseminomatous germ-cell tumors. We describe utilization of primary RPLND in the United States and report on overall survival (OS) after surgery for these men.

Patients And Methods: Using 2004-2014 data from the National Cancer Data Base, we identified 62,727 men with primary testicular cancer, 31,068 of whom were diagnosed as having seminoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.10.018DOI Listing
April 2020
1.693 Impact Factor

Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.

J Natl Compr Canc Netw 2019 12;17(12):1529-1554

National Comprehensive Cancer Network.

Testicular cancer is relatively uncommon and accounts for <1% of all male tumors. However, it is the most common solid tumor in men between the ages of 20 and 34 years, and the global incidence has been steadily rising over the past several decades. Several risk factors for testicular cancer have been identified, including personal or family history of testicular cancer and cryptorchidism. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2019.0058DOI Listing
December 2019

Differences in PD-L1-Expressing Macrophages and Immune Microenvironment in Testicular Germ Cell Tumors.

Am J Clin Pathol 2020 02;153(3):387-395

Department of Anatomic Pathology, Hospital of the University of Pennsylvania, Philadelphia.

Objectives: To characterize the tumor microenvironment of testicular germ cell tumors (GCTs) using immunohistochemical markers.

Methods: Seventy-seven orchiectomies, including 36 nonmetastatic (NM) seminomas, 15 metastatic (M) seminomas, 13 nonmetastatic nonseminomatous germ cell tumors (NSGCTs), and 13 metastatic NSGCTs, were studied with PD-1, PD-L1, FOXP3, CD68, CD163, and mismatch repair (MMR) immunohistochemistry. FOXP3+ and PD-1+ tumor-infiltrating lymphocytes (TILs) and tumor-associated macrophages (TAMs) expressing CD68 and CD163 were enumerated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ajcp/aqz184DOI Listing
February 2020

Somatic Malignant Transformation of a Testicular Teratoma: A Case Report and an Unusual Presentation.

Case Rep Pathol 2019 3;2019:5273607. Epub 2019 Nov 3.

Department of Pathology, University of Toledo Medical Center, Toledo, OH, USA.

Testicular cancer represents 1% of all malignant tumors in men. About 95% of testicular cancers are germ cell tumors (GCTs). These can be divided into nonseminomatous GCTs (NSGCTs) and seminomas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/5273607DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6874974PMC
November 2019

Massive Intra-abdominal Germ Cell Tumors: A Case Series and Review of Literature.

Rev Urol 2019 ;21(2-3):136-140

University of Texas Southwestern Medical Center Dallas TX.

Intra-abdominal testes are at increased risk of malignant transformation and can manifest as large abdominal masses with a wide variation in presenting symptoms. In the setting of cryptorchid or nonpalpable testes, large abdominal masses are highly suspect for germ cell tumors. Without standard guidelines, management can vary extensively. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6864910PMC
January 2019

Primary and Recurrent Growing Teratoma Syndrome in Central Nervous System Nongerminomatous Germ Cell Tumors: Case Series and Review of the Literature.

World Neurosurg 2020 Feb 18;134:e360-e371. Epub 2019 Nov 18.

Department of Neurosurgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. Electronic address:

Background: The term "growing teratoma syndrome (GTS)" has been used as follows: patients with germ cell tumor (GCT) who present with enlarging original/metastatic masses during or after appropriate systemic chemotherapy despite normalized serum markers. In other words, the definition of the term GTS is not fully established. We analyzed and reviewed our case series regarding GTS that developed after the treatment of central nervous system (CNS) nongerminoatous germ cell tumors (NGGCTs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.wneu.2019.10.074DOI Listing
February 2020
2.417 Impact Factor

Gemcitabine, paclitaxel, and oxaliplatin (GEMPOX) in the treatment of relapsed/refractory intracranial nongerminomatous germ cell tumors.

Pediatr Blood Cancer 2020 02 14;67(2):e28089. Epub 2019 Nov 14.

Department of Pediatric Oncology, Hospital Universitario Niño Jesús, Madrid, Spain.

Intracranial germ cell tumors (GCT) account for less than 5% of all central nervous system tumors in children in Western countries. Approximately 40% are nongerminomatous GCT (NGGCT). Despite correct treatment, 16% to 47% of the patients will relapse. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pbc.28089DOI Listing
February 2020

Differentiation of testicular seminoma and nonseminomatous germ cell tumor on magnetic resonance imaging.

Medicine (Baltimore) 2019 Nov;98(45):e17937

Urogenital System Group, Department of Radiology, People's Hospital of Long Hua District.

Magnetic resonance imaging (MRI) has excellent soft tissue resolution, as well as multidirectional and multisequence scanning technology, making it an important supplementary method in the diagnosis of testicular tumor.To explore the utility of preoperative MRI for the differential diagnosis of testicular seminoma and nonseminomatous germ cell tumors (NSGCTs).The medical records from 39 patients with testicular tumors that were examined preoperatively with MRI and treated with urologic surgery at our institution between January 2015 and March 2019 were retrospectively reviewed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000017937DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6855626PMC
November 2019

Laparoscopic Resection of Residual Retroperitoneal Tumor Mass in Advanced Nonseminomatous Testicular Germ Cell Tumors; a Feasible and Safe Oncological Procedure.

Sci Rep 2019 11 1;9(1):15837. Epub 2019 Nov 1.

Department of Surgical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Ten-year oncological experience of the University Medical Center Groningen with conventional laparotomy (C-RRRTM) and laparoscopy (L-RRRTM) is described concerning resection of residual retroperitoneal tumor masses (RRTM) in a large series of patients with advanced nonseminomatous testicular germ cell tumors (NSTGCT). 150 consecutive patients with disseminated NSTGCT required adjunctive surgery after combination chemotherapy. L-RRRTM was scheduled in 89 and C-RRRTM in 61 patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-019-52109-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6825184PMC
November 2019

Intracranial Germ Cell Tumors in Adolescents and Young Adults: A 40-Year Multi-Institutional Review of Outcomes.

Int J Radiat Oncol Biol Phys 2020 02 22;106(2):269-278. Epub 2019 Oct 22.

Princess Margaret Cancer Centre, Toronto, Ontario; University of Toronto, Toronto, Ontario; The Hospital for Sick Children, Toronto, Ontario.

Purpose: The aim of this study was to determine the practice patterns and outcomes of intracranial germ cell tumors (IGCT) in adolescents and young adults according to different therapeutic approaches.

Methods And Materials: One-hundred twelve patients with IGCT aged 15 to 39 years were managed at either XX or the XY center from 1975 to 2015. The charts were retrospectively reviewed and data collected. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2019.10.020DOI Listing
February 2020
1 Read
4.258 Impact Factor

Performance Characteristics of Clinical Staging Modalities for Early Stage Testicular Germ Cell Tumors: A Systematic Review.

J Urol 2020 05 14;203(5):894-901. Epub 2020 Oct 14.

The Johns Hopkins Evidence-Based Practice Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.

Purpose: We synthesized evidence on the comparative performance characteristics, benefits and harms of diagnostic imaging modalities used in combination with serum tumor markers for clinical staging of testicular germ cell tumors. The diagnostic imaging modalities included computerized tomography, magnetic resonance imaging, positron emission tomography and chest radiographs.

Materials And Methods: Paired reviewers independently searched PubMed, Embase® and the Cochrane Central Register of Controlled Trials from 1980 to 2018 using title-abstract and full-text screening to identify original studies of the use of computerized tomography, magnetic resonance imaging, positron emission tomography, chest radiographs and serum tumor markers for the clinical staging of early stage testicular germ cell tumors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JU.0000000000000594DOI Listing
May 2020
1 Read

Current management of stage I testicular germ cell tumors in a French cancer institute. A practice analysis over the 10 past years.

Bull Cancer 2019 Dec 30;106(12):1086-1093. Epub 2019 Sep 30.

Institut de cancérologie Lucien-Newirth, Department of Medical Oncology, Saint-Priest-en-Jarez, France.

Background: Testicular Germ Cell Tumors (TGCTs) represent the most frequent malignant tumour among young male adults. Orchiectomy alone cure 80% of stage I. Standard options after orchiectomy include radiotherapy (RT), chemotherapy (CT) by 1 cycle of carboplatin AUC 7 or active surveillance (SV) for seminomatous GCTs (SGCT) and retroperitoneal lymphadenectomy (RPLND), CT by 1 or 2 cycles of Bleomycine Etoposide Cisplatine (BEP) or active surveillance for nonseminomatous GCTs (NSGCT). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2019.08.012DOI Listing
December 2019

Imaging of Metastatic Germ Cell Tumors in Male Patients From Initial Diagnosis to Treatment-Related Toxicities: A Primer for Radiologists.

AJR Am J Roentgenol 2020 01 1;214(1):24-33. Epub 2019 Oct 1.

Department of Imaging, Dana-Farber Cancer Institute and Harvard Medical School, 450 Brookline Ave, Boston, MA 02215.

This review describes the influence of histology and metastatic sites on prognosis in male patients with metastatic germ cell tumors (GCTs) and explains the role imaging in assessing therapeutic response, residual disease, recurrence, sand treatment-related toxicities. Seminomatous and nonseminomatous GCTs differ in imaging appearance, pattern of spread, and prognosis, and an organ-based approach is helpful in prognostication. Multimodality imaging aids in accurate staging, prognostication, characterization of treatment response, and identification of therapy-related toxicity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2214/AJR.19.21623DOI Listing
January 2020
2 Reads

A Rare Case of Mediastinal Non-seminomatous Germ Cell Tumour with Acute Megakaryocytic Leukaemia.

J Assoc Physicians India 2019 Jul;67(7):88-89

Resident, Dept. of Medicine, INHS Asvini, Mumbai, Maharashtra.

The most common extragonadal site of Nonseminomatous Germ Cell Tumours is the mediastinum. These are similar to their gonadal counterparts in histology but have a poorer prognosis. The association of mediastinal germ cell tumours with blood borne malignancies has been established in many case reports. Read More

View Article

Download full-text PDF

Source
July 2019
1 Read

Does multiparametric US improve diagnostic accuracy in the characterization of small testicular masses?

Gland Surg 2019 Sep;8(Suppl 3):S136-S141

Radiology and Radiotherapy Unit, Department of Precision Medicine, University of Campania "L. Vanvitelli", Naples, Italy.

Background: Recent advances in ultrasonography (US) have produced new innovative techniques for the non-invasive assessment of testicular masses. The aim of this study was to investigate the diagnostic performance of multiparametric US, including gray-scale, Color-power Doppler and real-time elastography (RTE) analysis, in the characterization of testicular lesions.

Methods: Fifty-four patients (median 42. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/gs.2019.04.03DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6755944PMC
September 2019
3 Reads

External validation of 2 models to predict necrosis/fibrosis in postchemotherapy residual retroperitoneal masses of patients with advanced testicular cancer.

Urol Oncol 2019 11 17;37(11):809.e9-809.e18. Epub 2019 Sep 17.

Department of Urology, University Hospital Cologne, Cologne, Germany; Department of Urology, Medical University Vienna, Austria. Electronic address:

Objectives: Nonseminomatous testicular germ cell tumors with residual retroperitoneal lesions >1 cm are treated with postchemotherapy retroperitoneal lymph node dissection (pcRPLND). However, up to 50% of patients are overtreated since the histology shows only residual necrosis/fibrosis. We aim to validate the 2 currently best performing prediction models (Vergouwe and Leao) for postchemotherapy residual mass histology. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2019.07.021DOI Listing
November 2019
1 Read

Nucleolin and nucleophosmin expression in seminomas and non-seminomatous testicular tumors.

Folia Histochem Cytobiol 2019 12;57(3):139-145. Epub 2019 Sep 12.

Department of Pathology, Pomeranian Medical University, Szczecin, Poland.

Introduction: Testicular tumors are heterogeneous group of neoplasms divided mainly into two types: seminomas and non-seminomas. Nucleolin (NCL) and nucleophosmin (NPM) are abundant nucleolar proteins involved in many physiologic and pathologic processes including cancer. Their overexpression was found in many tumors but it was not studied in testicular cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5603/FHC.a2019.0015DOI Listing
December 2019
4 Reads

Primary robotic RLPND for nonseminomatous germ cell testicular cancer: a two-center analysis of intermediate oncologic and safety outcomes.

World J Urol 2020 Apr 9;38(4):859-867. Epub 2019 Sep 9.

Department of Urology, Mayo Clinic, Phoenix, AZ, USA.

Objective: To evaluate the intermediate-term oncologic outcomes and safety profile of the largest case series of primary robotic retroperitoneal lymphadenectomy for low-clinical-stage non-seminomatous germ cell testicular cancer.

Methods: This was a two-center retrospective analysis of robotic RPLND cases for low-clinical-stage (stage I-IIB) non-seminomatous germ cell testicular cancer in the primary setting. Demographic, perioperative, operative and oncologic variables were collected between March 2008 and May 2019. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00345-019-02900-w
Publisher Site
http://dx.doi.org/10.1007/s00345-019-02900-wDOI Listing
April 2020
4 Reads

Interobserver Agreement in Vascular Invasion Scoring and the Added Value of Immunohistochemistry for Vascular Markers to Predict Disease Relapse in Stage I Testicular Nonseminomas.

Am J Surg Pathol 2019 12;43(12):1711-1719

Labaoratory for Experimental Patho-Oncology (LEPO), Department of Pathology, Erasmus MC-University Medical Center Rotterdam, Cancer Institute, Rotterdam, The Netherlands.

Vascular invasion has been identified as an informative risk factor for relapse in stage I testicular nonseminomas, used to tailor treatment. We investigated interobserver agreement in vascular invasion reporting and studied the potential additional value of immunohistochemistry for vascular markers for predicting relapse. Patients (n=52) with stage I testicular nonseminomas undergoing surveillance (1993-2006) were included (median follow-up of 66 mo). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAS.0000000000001352DOI Listing
December 2019

A Population-Based Analysis of Incidence, Mortality, and Survival in Testicular Cancer Patients in Lithuania.

Medicina (Kaunas) 2019 Aug 30;55(9). Epub 2019 Aug 30.

Laboratory of Cancer Epidemiology, National Cancer Institute, 08406 Vilnius, Lithuania.

The aim of this study was to analyze trends in testicular cancer incidence, mortality, and survival in Lithuania during the period 1998-2013. The study was based on all cases of testicular cancer reported to the Lithuanian Cancer Registry between 1998 and 2013. Age group-specific rates and standardized rates were calculated using the direct method (European standard population). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/medicina55090552DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6780107PMC
August 2019
2 Reads

CXCL12 expression is an adverse predictor for disease recurrence in patients with metastatic non-seminomatous testicular germ cell tumors.

BMC Cancer 2019 Aug 14;19(1):802. Epub 2019 Aug 14.

Department of Urology, University Hospital, University of Zurich, Zurich, Switzerland.

Background: To validate the utility of the chemokine ligand 12 (CXCL12) as prognostic marker in patients with localized and metastatic germ cell tumors (GCT).

Methods: CXCL12 expression was analyzed on a tissue microarray consisting of 750 tissue cores of different histological tumor components, Germ cell neoplasia in situ (GCNIS) and adjacent normal tissue of 263 testicular cancer patients using a semi-quantitative score. The association between CXCL12 expression and recurrence-free survival (RFS) as well as overall survival (OS) was assessed using Kaplan-Meier curves with log-rank tests. Read More

View Article

Download full-text PDF

Source
https://bmccancer.biomedcentral.com/articles/10.1186/s12885-
Publisher Site
http://dx.doi.org/10.1186/s12885-019-5961-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6693197PMC
August 2019
4 Reads

Wnt suppressor and stem cell regulator TCF7L1 is a sensitive immunohistochemical marker to differentiate testicular seminoma from non-seminomatous germ cell tumor.

Exp Mol Pathol 2019 10 2;110:104293. Epub 2019 Aug 2.

Department of Laboratory Medicine and Pathology, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN 55455, United States of America; Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642, United States of America; Lillehei Heart Institute and Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, United States of America. Electronic address:

The accurate classification and proper identification of testicular germ cell tumors is imperative for treatment selection and clinical prognosis. Although such distinction can often be achieved by microscopic morphology alone, ancillary tests may at times be needed. T-cell factor 7 L1 (TCF7L1, also known as TCF3), a component of the Wnt signaling pathway, plays important roles in embryonic stem cell self-renewal and lineage specification. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.yexmp.2019.104293DOI Listing
October 2019
7 Reads
2.706 Impact Factor

Improving the Prognostic Ability for Personalized Therapeutic Approaches in Nonseminomatous Germ Cell Tumors.

J Clin Oncol 2019 09 30;37(26):2314-2316. Epub 2019 Jul 30.

Moffitt Cancer Center and Research Institute, Tampa, FL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.19.01672DOI Listing
September 2019

Site of extranodal metastasis impacts survival in patients with testicular germ cell tumors.

Cancer 2019 11 29;125(22):3947-3952. Epub 2019 Jul 29.

Department of Urology, University of Texas Southwestern, Dallas, Texas.

Background: Using a large, nationally representative, population-based cancer registry, this study systematically evaluated the impact of the location and burden of extranodal testicular germ cell tumor (TGCT) metastases on survival.

Methods: Men with stage III TGCTs captured by the Surveillance, Epidemiology, and End Results registry from 2010 to 2015 with distant extranodal metastases were identified. Clinicopathologic information was collected, and patients were subdivided according to the specific organ site or sites of metastatic involvement (lung, liver, bone, and/or brain). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.32427DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6819223PMC
November 2019
5 Reads

Management, Treatment, and Molecular Background of the Growing Teratoma Syndrome.

Urol Clin North Am 2019 Aug 29;46(3):419-427. Epub 2019 May 29.

Department of Urology, University of Duesseldorf, Medical Faculty, Heinrich-Heine-University, Moorenstr. 5, Duesseldorf 40225, Germany.

Growing teratoma syndrome (GTS) is a rare clinical phenomenon in patients with nonseminomatous germ cell cancer defined by growing metastatic mass during ongoing or directly after completed chemotherapy with timely decreasing tumor markers and postpubertal teratoma exclusively after resection. GTS was first described in 1982, and few reports have been published. The limited number of studies and the resulting lack of exact knowledge about development, differentiation, and treatment of GTS leaves several clinical problems regarding treatment and follow-up unsolved. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ucl.2019.04.008DOI Listing
August 2019
4 Reads
1.347 Impact Factor

Postchemotherapy Resection of Residual Mass in Nonseminomatous Germ Cell Tumor.

Urol Clin North Am 2019 Aug 21;46(3):389-398. Epub 2019 May 21.

Norris Comprehensive Cancer Center, USC Institute of Urology, 1441 Eastlake Avenue, Suite 7416, Los Angeles, CA 90033, USA. Electronic address:

The introduction of cisplatin-based chemotherapy has revolutionized the care of patients with disseminated testicular germ cell tumors. Although a majority are cured with chemotherapy alone, surgical resection continues to play a role because one-third will have residual mass after chemotherapy. In this article, we review the current indications for postchemotherapy resection in nonseminomatous germ cell tumors, including masses greater than 1 cm, resection after salvage chemotherapy, with elevated markers, after late relapse, and for growing teratoma syndrome. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ucl.2019.04.004DOI Listing
August 2019
9 Reads

Nationwide Patterns of Care for Stage II Nonseminomatous Germ Cell Tumor of the Testicle.

Eur Urol Oncol 2020 Apr 1;3(2):198-206. Epub 2019 Jul 1.

Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. Electronic address:

Background: Management strategies for advanced testicular cancer published from a few, high-volume clinical centers may not be generalizable.

Objective: To discern treatment patterns for stage II nonseminomatous germ cell tumor (NSGCT) in a nationwide cancer registry.

Design, Setting, And Participants: The National Cancer Database was queried for patients with a stage II NSGCT from 2004 to 2014. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euo.2019.06.007DOI Listing
April 2020
4 Reads

What Is the Significance of Rete Testis Invasion by Malign Germ Cell Tumor and Does Hilum Predict Metastasis?

Urol Int 2019 14;103(1):49-54. Epub 2019 Jun 14.

Department of Pathology, Umraniye Education and Research Hospital, Istanbul, Turkey.

Background: The significance of hilar soft tissue invasion of rete testis in malign germ cell tumors is still controversial on current guidelines.

Objectives: We aimed to investigate the importance of hilar soft tissue involvement in germ cell tumors and evaluated the possibility of a risk factor such as rete testis.

Method: Totally, 59 radical orchiectomy specimens operated between 2007 and 2015 at our clinics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000500959DOI Listing
February 2020
15 Reads

Management of Stage II Germ Cell Tumors: Be Sure, Be Patient, Be Safe.

J Clin Oncol 2019 08 10;37(22):1856-1862. Epub 2019 Jun 10.

2Testicular Cancer Commons, Vancouver, WA.

A healthy 27-year-old man discovered a left testicular mass. Several months later he saw an urologist, who palpated a suspicious mass on the left testicle; an ultrasound confirmed a 2-cm solid mass. Serum tumor marker testing disclosed a slightly elevated alpha-fetoprotein (AFP) of 12. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.19.00502DOI Listing
August 2019
19 Reads

Successful treatment of metachronous contralateral intratubular germ cell neoplasia with partial orchiectomy and low-dose radiation in a patient previously treated for testicular carcinoma.

Pediatr Blood Cancer 2019 10 9;66(10):e27872. Epub 2019 Jun 9.

Department of Pediatrics, Baylor College of Medicine, Houston, Texas.

Intratubular germ cell neoplasia (ITGCN) of the testis is a precursor to testicular germ cell tumor (TGCT), which can lead to the development of invasive cancer. In patients with a history of previously treated unilateral TGCT, treatment for ITGCN of the contralateral testis needs to be balanced with the risks of subsequent infertility. Here, we present a 17- year- old patient with ITGCN diagnosed after treatment of contralateral nonseminomatous TGCT who was successfully treated with a partial orchiectomy followed by low-dose radiation with preservation of his testosterone production. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pbc.27872DOI Listing
October 2019
7 Reads

Treatment and Outcome of Patients with Stage IS Testicular Cancer: A Retrospective Study from the Spanish Germ Cell Cancer Group.

J Urol 2019 10 6;202(4):742-747. Epub 2019 Sep 6.

Hospital Universitario Son Espases, Palma de Mallorca, Spain.

Purpose: Stage IS testicular cancer is defined by the persistence of elevated serum tumor markers, including α-fetoprotein and/or β-human chorionic gonadotropin, after orchiectomy without radiological evidence of metastatic disease. Current treatment recommendations include cisplatin based chemotherapy up front but the recommendations are based on limited single center series.

Materials And Methods: We retrospectively analyzed clinical and pathological characteristics, and long-term outcomes in 110 patients uniformly treated with primary chemotherapy between 1994 and 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JU.0000000000000366DOI Listing
October 2019
8 Reads

[Sexual dysfunctions of patients treated with orchidectmoy, chemotherapy and retroperitoneal lymphadenectomy, need for systematic andrological care?]

Bull Cancer 2019 Oct 22;106(10):915-922. Epub 2019 May 22.

Centre hospitalier universitaire, Hôtel-Dieu, service d'urologie, 44000 Nantes, France.

Goal: Long-term evaluation of the incidence of sexual dysfunction from patients who were treated by orchidectomy, chemotherapy, and retroperitoneal lymphadenectomy for testicular cancer.

Methods: In 2018, patients who were treated in two academic hospitals by orchiectomy, chemotherapy, and retroperitoneal lymphadenectomy, and were in complete remission, were included. The patients included in this study filled the survey, which covered aspects of their sexuality (the Male Sexual Health Questionnaire) and answered additional questions, which evaluated psychological impact and modification of their sexuality since the management of their cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2019.03.020DOI Listing
October 2019
4 Reads

Stereotactic Ablative Radiotherapy (SAbR) in the Setting of Metastatic Nonseminomatous Germ Cell Tumor of Testis.

Clin Genitourin Cancer 2019 08 26;17(4):e768-e771. Epub 2019 Apr 26.

Department of Urology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.04.005DOI Listing
August 2019
2 Reads

Testicular Mixed Germ Cell Tumor in a Newborn Child: A Rare Case.

J Indian Assoc Pediatr Surg 2019 Apr-Jun;24(2):144-146

Department of Pediatric Surgery, SMS Medical College, Jaipur, Rajasthan, India.

Testicular tumors are rare in children but highly treatable and usually curable. Seminomas are extremely rare in prepubertal children. Among nonseminomatous germ cell tumors, the most common are teratomas and yolk sac tumors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/jiaps.JIAPS_87_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6417042PMC
May 2019
8 Reads

[Testicular tumors: A diagnostic challenge of imaging].

Bull Cancer 2019 Oct 12;106(10):875-886. Epub 2019 May 12.

Institut Gustave-Roussy, département d'oncologie, 114, rue Edouard-Vaillaxnt, 94805 Villejuif, France.

Objectives: Reviewing the characterization and the follow-up imaging of testicular tumors.

Material And Methods: Literature review (PubMed, Medline) of urological and radiological studies dealing with testicular tumors using keywords: Testicular tumors; Color Doppler ultrasound; US elastography; Magnetic resonance imaging; Contrast enhanced sonography.

Results: Ultrasound remains the basic exam for the tumor characterization. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00074551193015
Publisher Site
http://dx.doi.org/10.1016/j.bulcan.2019.03.008DOI Listing
October 2019
22 Reads

[Stage 1 germ-cell tumour].

Bull Cancer 2019 Oct 12;106(10):887-895. Epub 2019 May 12.

Gustave Roussy, département de médecine oncologique, 114, rue Edouard-Vaillant, 94805 Villejuif, France. Electronic address:

Stage I germ-cell tumors are rare and highly curable diseases. As such, management of these tumours should carefully follow guidelines. Initial management is based on orchiectomy and several options as adjuvant therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2019.03.010DOI Listing
October 2019
8 Reads

Primary mediastinal germ cell tumors.

Semin Oncol 2019 04 24;46(2):107-111. Epub 2019 Apr 24.

Division of Medical Oncology, Fondazione IRCCS Policlinico San Matteo and University of Pavia, Italy; Cellular Therapy and Immunobiology Working Party, EBMT.

Backgroud: Germ cell tumors (GCTs) are a group of neoplasms usually arising in the gonads, and very rarely in sites outside the gonads, mainly in the retroperitoneum, the anterior mediastinum, and pineal gland or the coccyx (mainly in childhood). The prognosis of nonseminoma primary mediastinal GCTs (PMGCTs), is considered to be poorer compared to its retroperitoneal or gonadal counterparts and, according to the International Germ Cell Cancer Collaborative Group, it is considered by definition as a "poor risk" disease.

Material And Methods: Our review highlights the clinical features, prognostic factors, and therapeutic strategies in PMGCTs, as described in medical literature. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2019.04.001DOI Listing
April 2019
11 Reads